Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Obituary: Barry Sherman

Executive Summary

Apotex has paid its respects to the company’s founder and chairman, Barry Sherman, 75, and his wife Honey, 70, after they were found dead at their home in Toronto, Canada, on 15 December. The Canadian firm said it was with “profound sadness that we announce the unexpected passing” of Sherman, who founded privately-held Apotex in 1974. “From its humble two-employee, 5,000 square-feet beginning in Toronto, the company Dr Sherman founded grew into a global pharmaceutical organisation that today employs more than 11,000 people in research, development, manufacturing and distribution in facilities around the world,” Apotex commented.

You may also be interested in...

A New Era: Apotex Gets Fresh Leadership As SK Completes Acquisition

As SK Capital Partners completes its acquisition of Apotex, generics industry veteran Allan Oberman has been named as the new president and CEO of the Canadian giant, replacing Jeff Watson who will remain on the company’s board.

OTC Private Label, Rx Generics Firm Apotex To Be Acquired By Private Investment Group

SK Capital announced agreement to acquire Apotex, saying it will invest to “support Apotex’s next phase of growth and continued innovation for patient affordability."

Canada’s Apotex Is Snapped Up By SK Capital

Apotex is to be acquired by SK Capital, the private investment firm has announced. The Canadian generics giant’s new owner has promised to invest in the firm to “support Apotex’s next phase of growth and continued innovation for patient affordability.”

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts